Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSL | P07711 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 7/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | KYNU | Q16719 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198823 | 0.91 | KYNU (0.56) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL1198821 | 0.91 | KYNU (0.56) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL4411654 | 0.90 | CTSL (0.51) | CTSSCTSLCTSBCTSKITGB3 | |
| SCHEMBL4411661 | 0.90 | CTSL (0.51) | CTSSCTSLCTSBCTSKITGB3 | |
| SCHEMBL346550 | 0.88 | CTSL (0.54) | CTSSCTSLCTSBCTSKITGB3 | |
| SCHEMBL346551 | 0.88 | CTSL (0.54) | CTSSCTSLCTSBCTSKITGB3 | |
| SCHEMBL4314391 | 0.88 | SIRT2 (0.52) | CTSSCTSLCTSBCTSKITGB3 | |
| SCHEMBL4314399 | 0.88 | SIRT2 (0.52) | CTSSCTSLCTSBCTSKITGB3 | |
| SCHEMBL346954 | 0.87 | CTSS (0.58) | CTSSCTSLCTSBCTSKITGB3 | |
| SCHEMBL346953 | 0.87 | CTSS (0.58) | CTSSCTSLCTSBCTSKITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CTSS 24/4885CTSL 9/4885CTSB 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.